Lipocine (LPCN) Fundamental Analysis: Revenue, Earnings & Valuation

4.77 / 10

Netural

The fundamental framework scores 4.8/10 - moderate quality. Supporting factors: Fixed assets turnover ratio and Interest coverage ratio (EBIT / Interest expense) (%), though challenges appear in Asset-MV and Total operating revenue (YoY growth rate %). Overall perspective: cautious.

Analysis Checks(7/10)

Revenue-MV

Value-2.15

Score3/3

Weight58.39%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value-82.35

Score1/3

Weight-5.36%

1M Return-1.04%

Inventory turnover ratio

Value98.02

Score2/3

Weight-6.12%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight25.48%

1M Return4.10%

PB-ROE

Value1.47

Score2/3

Weight28.12%

1M Return4.39%

Fixed assets turnover ratio

Value14.68

Score2/3

Weight-7.06%

1M Return-1.33%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-5.68%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value-82.35

Score1/3

Weight-5.34%

1M Return-1.04%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight-7.12%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight24.69%

1M Return3.90%

Is LPCN undervalued or overvalued?

LPCN scores 4.77/10 on fundamentals and holds a Fair valuation at present. Backed by its -54.28% ROE, -487.05% net margin, -1.55 P/E ratio, 1.03 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.